Background Tacrolimus is a key drug in kidney transplantation with a narrow therapeutic
index. However, whether tacrolimus exposure variability affects clinical outcomes and …

The pharmacokinetics of Tacrolimus is characterized by a high interindividual variability that
is mainly explained by pharmacogenetics biomarkers. The aims were to develop a …

Backgrounds Tacrolimus (TAC) concentration in peripheral blood mononuclear cells
(PBMCs) is regarded as a better predictor of its immunosuppressive effect than the TAC …

Introduction: Tacrolimus is metabolized mainly in the liver by the CYP3A enzyme family, with
a particularly well-documented role of CYP3A5. CYP3A5 is also expressed in the renal …

Tacrolimus (Tac) is an effective remission inducer of refractory ulcerative colitis (UC). Gene
polymorphisms result in interindividual variability in Tac pharmacokinetics. In this study, we …

Background: There are inconsistent findings regarding the relationship between trough
whole blood tacrolimus concentration (TAC C 0) and acute kidney rejection in recipients …

Background Innate immunity contributes to acute rejection after kidney transplantation.
Genetic polymorphisms affecting innate immunity may therefore influence patients' risk of …

Background After renal transplantation, immunosuppressants should be administered to
prevent organ rejection and prolong graft survival. One of them is tacrolimus, which is …

Pharmacogenomic (PGx) testing can potentially improve care post-solid organ
transplantation (SOT). However, adoption of PGx testing has been slow in the SOT setting …

Heart transplantation (HTx) continues to be the gold standard treatment for patients with
advanced heart failure. Following HTx, patients are placed on a lifelong regimen of …